Impact of Trans Fatty Acids From Natural and Industrial Origin in the Induction of Insulin Resistance Development

NCT ID: NCT00617435

Last Updated: 2025-11-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

66 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-10-31

Study Completion Date

2009-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators' project has as for principal objective to understand the impact of trans fatty acids from dairy products and industrial origin on the development of insulin resistance in obese woman. Because of the different isomeric position of the double bound those trans fatty acids may have different metabolic effects.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Women will be included in the study according to their susceptibility to develop a insulin resistance (evaluated starting from the body index of mass IMC superior to 28 kg.m-², of the waist measurement 88 cm). Once included in the study, the volunteers will receive for 4 weeks butter, dairy products and biscuits enriched in stearic, elaidic or vaccenic acid. The volunteers will undergo a measurement of the body composition by biphotonic absorptiometry as well as a complete metabolic assessment (blood and urinary samples, clamp to insulin and biopsies).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Insulin Resistance Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

V

Group Type EXPERIMENTAL

vaccenic acid enriched diet

Intervention Type DIETARY_SUPPLEMENT

The experimental milk fat, entitled "vaccenic acid enriched milk fat" (VAMF), has been obtained by feeding cows with a diet containing sunflower oil.

N

Group Type EXPERIMENTAL

Elaidic acid enriched diet

Intervention Type DIETARY_SUPPLEMENT

Mixture of vegetable oils (including partially hydrogenated oils)

J

Group Type EXPERIMENTAL

control diet

Intervention Type DIETARY_SUPPLEMENT

Mixed of different oil

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

vaccenic acid enriched diet

The experimental milk fat, entitled "vaccenic acid enriched milk fat" (VAMF), has been obtained by feeding cows with a diet containing sunflower oil.

Intervention Type DIETARY_SUPPLEMENT

Elaidic acid enriched diet

Mixture of vegetable oils (including partially hydrogenated oils)

Intervention Type DIETARY_SUPPLEMENT

control diet

Mixed of different oil

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* female
* waist measurement \> 88 cm
* body mass index\> 28kg/m2
* Affiliated to National Health Insurance
* Subject giving his/her written informed consent
* Subject willing to comply with the study procedures
* Subject considered as normal after clinical examination and medical questionnaire

Exclusion Criteria

* Reported food allergies
* Currently participating or having participated in another clinical trial during the last 4 weeks prior to the beginning of this study
* Hepatic or renal impairments
* Positive serologies to HIV or HCV, determined on blood sample
* pregnant or presently attempting to get pregnant or menopause or lactating Blood donation done less than 2 months before the start of the study
* Chronic pathologies: diabetes, hypertriglyceridemia, hypertension, cardiovascular diseases, chronic inflammatory diseases
* Intestine, cardiovascular, kidney and cancer pathologies in the last 5 years
* Previous heavy intestine surgery (except appendicectomy)
* Previous medical and/or surgery judged by the investigator as incompatible with this study
* High variation (\> 5%) of body weight during the last 3 months
* Consuming nutritional supplements which could interfered with lipid metabolism (fish oil capsule, vitamins, soja lecithins,…)
* Heavy consumer of alcohol
* Smoker or ex-smoker who stopped smoking less than 1 month before V0 (more than 5 cigarettes/dy).
* Practising intensive physical exercise (\> 5 h per week)
* Vegetarian or vegan
* Being under someone's supervision
* Refusal to be registered on the National Volunteers Data file
* Disliking butter, margarine, cheese, biscuits and/or vegetable oil
* Dietary habits unreliable to controlled food intake
* Being in exclusion on the National Volunteers Data file
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Yves Boirie, MD, PU-PH

Role: PRINCIPAL_INVESTIGATOR

UMR1019 INRA - Université Clermont1

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre de Recherche en Nutrition Humaine Auvergne

Clermont-Ferrand, , France

Site Status

Centre de Recherche en Nutrition Humaine Rhônes-Alpes

Lyon, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

References

Explore related publications, articles, or registry entries linked to this study.

Chardigny JM, Malpuech-Brugere C, Dionisi F, Bauman DE, German B, Mensink RP, Combe N, Chaumont P, Barbano DM, Enjalbert F, Bezelgues JB, Cristiani I, Moulin J, Boirie Y, Golay PA, Giuffrida F, Sebedio JL, Destaillats F. Rationale and design of the TRANSFACT project phase I: a study to assess the effect of the two different dietary sources of trans fatty acids on cardiovascular risk factors in humans. Contemp Clin Trials. 2006 Aug;27(4):364-73. doi: 10.1016/j.cct.2006.03.003. Epub 2006 Apr 24.

Reference Type BACKGROUND
PMID: 16632411 (View on PubMed)

Tardy AL, Lambert-Porcheron S, Malpuech-Brugere C, Giraudet C, Rigaudiere JP, Laillet B, Leruyet P, Peyraud JL, Boirie Y, Laville M, Michalski MC, Chardigny JM, Morio B. Dairy and industrial sources of trans fat do not impair peripheral insulin sensitivity in overweight women. Am J Clin Nutr. 2009 Jul;90(1):88-94. doi: 10.3945/ajcn.2009.27515. Epub 2009 May 27.

Reference Type DERIVED
PMID: 19474135 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AU679

Identifier Type: -

Identifier Source: secondary_id

2006-0132

Identifier Type: -

Identifier Source: secondary_id

2006-A00397-44

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The InterSat Study
NCT04418102 COMPLETED NA